The frequency of polyclonal HGSC is unknown, but potential for polyclonal cancer development has been indicated in BRCA1 mutation carriers, who commonly present with several p53 signatures and different pathogenic mutations of TP53 at risk-reducing salpingo-oophorectomy (51). This evidence concerns the gene BRCA1 and cancer.